Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.

ABSTRACT:

Objective

Reducing the burden of α-synuclein oligomeric species represents a promising approach for disease-modifying therapies against synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. However, the lack of efficient drug discovery strategies that specifically target α-synuclein oligomers has been a limitation to drug discovery programs.

Research design and methods

Here we describe an innovative strategy that harnesses the power of bimolecular protein-fragment complementation to monitor synuclein-synuclein interactions. We have developed two robust models to monitor α-synuclein oligomerization by generating novel stable cell lines expressing α-synuclein fusion proteins for either fluorescent or bioluminescent protein-fragment complementation under

SUBMITTER: Moussaud S 

PROVIDER: S-EPMC4608017 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature